This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Nanjing Immunophage Biotech Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jianbei Xi: Innovator in CD38 Inhibition
Introduction
Jianbei Xi is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that serve as CD38 inhibitors. His work is crucial in addressing diseases mediated by CD38, showcasing his commitment to advancing medical research.
Latest Patents
Jianbei Xi holds a patent for "Compounds and their uses as CD38 inhibitors." This invention provides compounds of Formula I that can be utilized as CD38 inhibitors. The patent details methods for producing these compounds, pharmaceutical compositions that include them, and their applications in treating diseases mediated by CD38.
Career Highlights
Jianbei Xi is associated with Nanjing Immunophage Biotech Co., Ltd., where he continues to innovate and contribute to the field. His work has led to the development of important therapeutic options that could potentially improve patient outcomes.
Collaborations
Some of his notable coworkers include Jianfei Wang and Guohuang Fan. Their collaboration enhances the research environment and fosters innovation within their projects.
Conclusion
Jianbei Xi's contributions to the field of CD38 inhibition exemplify the impact of dedicated inventors in advancing medical science. His work not only highlights his innovative spirit but also the importance of collaboration in achieving significant breakthroughs.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile